The Global Alzheimer’s Platform Foundation (GAP) has announced a strategic collaboration with Siemens Healthineers for the Bio-Hermes-002 study, an observational platform designed to evaluate biomarkers for Alzheimer’s disease and related dementias.
The study compares blood-based and digital biomarkers across a wide range of cognitive conditions, alongside MRI and PET imaging data, to generate insights that may support early prediction, detection, and diagnosis of neurodegenerative diseases.
Bio-Hermes-002 aims to assess the performance of individual and combined biomarkers in identifying pathologies associated with Alzheimer’s disease, including amyloid and tau proteins in the brain. Siemens Healthineers will participate as a licensed partner, building on earlier findings from the Bio-Hermes-001 study.
“We’re proud to have Siemens Healthineers as a valued partner in the Bio-Hermes-002 study,” said John Dwyer, President of GAP. “With a shared goal of speeding diagnostics and the discovery of therapies for neurodegenerative diseases, this collaboration will enhance our scale and better integrate the entire spectrum of blood markers and imaging technology that needs to be brought to bear on clinical practice and research. We anticipate making great progress across the entire neurological technology waterfront with Siemens Healthineers’ involvement and are eager to get started.”
Data generated from the study will be stored on the AD Workbench, a global cloud-based data platform developed under the Alzheimer’s Disease Data Initiative (ADDI), enabling researchers to access and analyse data across multiple sources.
“Partnering with GAP for the Bio?Hermes?002 study is a timely opportunity to better understand how blood?based and digital biomarkers may help identify patients for neuroimaging and treatment earlier,” said Arejas J. Uzgiris, PhD, head of Clinical and Technology Innovation for North America for Diagnostics at Siemens Healthineers. “Generating evidence for use of earlier and broader testing to inform downstream clinical pathways is a critical step toward improving diagnosis and access to care.”